Skip to Main Content

The nonprofit Sabin Vaccine Institute is taking over development of vaccines to protect against two species of Ebola and a related virus, Marburg, acquiring the rights from GSK, the two entities announced Tuesday.

The transfer of the rights for the vaccines will put back into development a vaccine that GSK had shelved after the West African Ebola outbreak of 2014-2016. No money is changing hands; GSK is giving the rights to the institute.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED